Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 15/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 15/20 | 0.71 |
| ▸ | ADRA1B | P35368 | 15/20 | 0.71 |
| ▸ | HTR1A | P08908 | 3/20 | 0.66 |
| ▸ | DRD2 | P14416 | 3/20 | 0.66 |
| ▸ | HTR2C | P28335 | 2/20 | 0.66 |
| ▸ | DRD4 | P21917 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7684196 | 1.00 | ADRA1D (0.71) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL7465866 | 0.87 | ADRA1D (0.74) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL7684737 | 0.87 | ADRA1D (0.77) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL7679467 | 0.87 | ADRA1D (0.77) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL7684152 | 0.86 | ADRA1D (0.69) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL7685638 | 0.86 | ADRA1D (0.69) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL7473669 | 0.85 | ADRA1D (0.87) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL8130941 | 0.85 | ADRA1D (0.86) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL7682614 | 0.84 | ADRA1D (0.71) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL7681613 | 0.84 | ADRA1D (0.71) | ADRA1DADRA1AADRA1BHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010008903-A1 | Therapeutic agents | BIRCH ALAN MARTIN (GB) | 2001-07-19 | — | — | US | claimed |
| US-6201004-B1 | CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, EATING, CARDIOVASCULAR, BRAIN, AND GASTROINTESTINAL DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-03-13 | — | — | US | claimed |
| US-6353002-B2 | DIOXINOINDOLE AND THIENOBENZODIOXIN COMPOUNDS WHICH ARE HT3 RECEPTOR ANTAGONISTS AND ARE USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2002-03-05 | — | — | US | disclosed |
| US-20010008903-A1 | Therapeutic agents | BIRCH ALAN MARTIN (GB) | 2001-07-19 | — | — | US | disclosed |
| US-6201004-B1 | CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, EATING, CARDIOVASCULAR, BRAIN, AND GASTROINTESTINAL DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008903-A1 | Therapeutic agents | GPR119, SNCA, HTR2B | ADRA1D 105/4885ADRA1A 162/4885ADRA1B 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.